George is currently President and Head of Corporate Development and Strategy at GRAIL, a health-care company focused on the early detection of cancer. Prior to joining GRAIL in 2018, he was Executive Vice President of Business Development for Celgene Corporation, where during his 9-year tenure he was responsible for a full array of business development including in-licensing, strategic collaborations, M&A, out-licensing and alliance management.

During his tenure at Celgene, George developed new models for corporate collaborations, and led a business development effort that saw Celgene become “Partner of Choice” according to Boston Consulting Group Survey data.

George was previously Vice President of Business Development, Licensing and Strategy at Novartis. Prior to Novartis, he was Vice President of R&D Business Development at Elan and Vice President of Corporate Development at Schwarz Pharma, where he led CNS acquisitions worldwide.

George holds a B.A. in Biology from the University of Virginia, a Ph.D. in Genetics from the University of Wisconsin-Madison, and he conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder.